|Dr. Guido Oelkers||CEO & Pres||23.4M||N/A||1965|
|Dr. Anders Ullman M.D., Ph.D.||Head of R&D and Chief Medical Officer||420k||N/A||1956|
|Mr. Henrik Stenqvist||Chief Financial Officer||N/A||N/A||1967|
|Mr. Thomas Kudsk Larsen||Head of Communication & Investor Relations||N/A||N/A||1974|
|Mr. Torbjörn Hallberg||Gen. Counsel and Head of Legal Affairs & HR||N/A||N/A||1969|
|Mr. Philip Wood||Head of Haematology||N/A||N/A||1968|
|Ms. Konstantina Karampela||Sr. Director of European Commercial Operations (Specialty Care and Partner Products)||N/A||N/A||N/A|
|Mr. Armin Reininger||Head of Medical & Scientific Affairs||N/A||N/A||1957|
|Mr. Norbert Oppitz||Head of International||N/A||N/A||1967|
|Mr. Sofiane Fahmy||Head of Europe||N/A||N/A||1972|
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.
Swedish Orphan Biovitrum AB (publ)’s ISS governance QualityScore as of 1 May 2022 is 4. The pillar scores are Audit: 4; Board: 3; Shareholder rights: 1; Compensation: 7.